基因编辑权威指南。
菜单
首页 学习 新闻 向 Atlas 提问
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

🧭 引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

⚡ 专家观点
你已经了解生物学基础,只需内容本身——简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式

Treatment · Diabetes

Hypoimmune islet cell therapy

Transplanted insulin-producing cells edited to be invisible to the immune system, so they can survive without immunosuppressive drugs.

Phase I cell therapyhypoimmunediabetes
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

简单说明

Replacement insulin-producing cells work — but the immune system destroys them unless the patient takes powerful drugs that suppress it, which carry their own serious risks. These cells are edited to remove the markers the immune system checks and to display a signal that says 'leave me alone'. In early work, transplanted cells survived and produced insulin without any immunosuppression.

深入了解

Hypoimmune engineering knocks out B2M and CIITA to remove MHC class I and II and overexpresses CD47 to inhibit natural killer and macrophage clearance. Sana Biotechnology reported survival and insulin production from hypoimmune-modified allogeneic islet cells transplanted without immunosuppression, published in the New England Journal of Medicine.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas9

Diseases

Diabetes

Genes

B2M

Companies

Sana Biotechnology
仅供教育参考 本页面为参考资源,不构成医疗建议。研究进展和监管状态会发生变化;请查看上方的最后更新日期,并对重要信息进行核实,以所列主要来源为准。